In April 2013, the Infectious Disease Society of America (IDSA) reported that the weak antibiotic pipeline does not match bacteria's increasing ability to develop resistance. Since 2009, only 2 new antibiotics were approved in the United States. The number of new antibiotics approved for marketing per year declines continuously. The report identified seven antibiotics against the Gram-negative bacilli (GNB) currently in phase 2 or phase 3 clinical trials. However, these drugs do not address the entire spectrum of resistance of GNB. Some of these antibiotics are combination of existent treatments:
In April 2013 , the Infectious Disease Society of America ( IDSA ) reported that the weak antibiotic pipeline does not match bacteria 's increasing ability to develop resistance . Since 2009 , only 2 new antibiotics were approved in the United States . The number of new antibiotics approved for marketing per year declines continuously . The report identified seven antibiotics against the Gram - negative bacilli ( GNB ) currently in phase 2 or phase 3 clinical trials . However , these drugs do not address the entire spectrum of resistance of GNB . Some of these antibiotics are combination of existent treatments :
How many antibiotics have been created in the last 7 years?
How many antibiotics have been created in the last 7 years ?
2
2